Omitting 5-FU bolus in mCRC: survival and toxicity outcomes

▸ TREATMENT

A retrospective multicentre cohort of 267 metastatic CRC patients compared bolus-free nbFOLFOX (n=141) with standard mFOLFOX6 (n=126), with or without bevacizumab or anti-EGFR therapy, to assess impact on progression-free survival and overall survival. (Contemp Oncol)